How Polivy Works Against Lymphoma
Polivy (polatuzumab vedotin-piiq) treats certain lymphomas by delivering a targeted toxin directly to cancer cells. It combines a monoclonal antibody that binds to CD79b—a protein overexpressed on B-cells in non-Hodgkin lymphomas—with a chemotherapy drug called MMAE (monomethyl auristatin E). Once bound, the antibody-drug conjugate enters the cell, releases MMAE, and disrupts microtubules, halting cell division and triggering cancer cell death.[1]
What Types of Lymphoma Does It Target?
Polivy is FDA-approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and rituximab (BR regimen) after at least two prior therapies. It's not approved as monotherapy and targets B-cell malignancies where CD79b is present.[1][2]
Standard Treatment Regimen
Patients receive Polivy intravenously at 1.8 mg/kg every 21 days for up to six cycles, alongside bendamustine (90 mg/m²) and rituximab (375 mg/m²). Treatment continues until disease progression or toxicity limits it. Premedication with antihistamines and acetaminophen reduces infusion reactions.[1][3]
How It Improves on Rituximab-Bendamustine Alone
In the Phase II GO29365 trial, Polivy plus BR extended median overall survival to 12.4 months versus 4.7 months with BR alone (hazard ratio 0.46). Progression-free survival also doubled. This stems from MMAE's bystander effect, killing nearby cancer cells even if not all express CD79b uniformly.[2][4]
Common Side Effects and Risks
Neutropenia (41%), thrombocytopenia (42%), and anemia occur frequently, often requiring dose delays. Peripheral neuropathy (40%) arises from MMAE and may be irreversible. Other issues include fatigue, diarrhea, and infections. Monitoring blood counts and neurologic symptoms is standard.[1][3]
Who Makes Polivy and Patent Status?
Roche/Genentech developed Polivy, approved by FDA in June 2019. Key U.S. patents cover the conjugate and methods of use, with expiration around 2031-2033. Check DrugPatentWatch.com for latest litigation or challenges.[5]
Sources
[1]: Polivy Prescribing Information (FDA)
[2]: NEJM: Polatuzumab Vedotin in Relapsed DLBCL (2019)
[3]: NCCN Guidelines: B-Cell Lymphomas (2024)
[4]: FDA Approval Summary (2019)
[5]: DrugPatentWatch: Polivy Patents